Two young stroke patients associated with regular intravenous immunoglobulin (IVIg) therapy

Yumiko Nakano, Takeshi Hayashi, Kentaro Deguchi, Kota Sato, Nozomi Hishikawa, Toru Yamashita, Yasuyuki Ohta, Yoshiki Takao, Tomohiro Morio, Koji Abe

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We recently experienced 2 young adult patients who developed ischemic stroke after regular intravenous immunoglobulin (IVIg) therapy for agammaglobulinemia with diagnosis of common variable immunodeficiency (CVID) in their childhood. Patient 1 was 26-year-old woman, who developed Wallenberg's syndrome 6 days after the last IVIg therapy, but had no further stroke recurrence with cilostazol later. Patient 2 was 37-year-old man, who developed recurrent cerebral infarction in the territory of bilateral lenticulostriate branches like branch atheromatous disease (BAD) several days after the IVIg therapy. However, he had no further stroke recurrence after bone marrow transplantation (BMT) therapy for his lymphoproliferative disorder. It was suggested that IVIg therapy was associated to these different types of ischemic stroke in our 2 young adult patients with minimal vascular risk factors. Although IVIg therapy is widely used as a relatively safe medication for immunodeficiency disorders or autoimmune diseases, we need to pay more attention to stroke occurrence with regular IVIg therapy.

Original languageEnglish
Pages (from-to)9-12
Number of pages4
JournalJournal of the Neurological Sciences
Volume361
DOIs
Publication statusPublished - Feb 15 2016

Fingerprint

Passive Immunization
Intravenous Immunoglobulins
Stroke
Young Adult
Lateral Medullary Syndrome
Common Variable Immunodeficiency
Recurrence
Agammaglobulinemia
Lymphoproliferative Disorders
Cerebral Infarction
Bone Marrow Transplantation
Autoimmune Diseases

Keywords

  • Agammaglobulinemia
  • Intravenous immunoglobulin
  • Stroke
  • Thrombotic complication

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Two young stroke patients associated with regular intravenous immunoglobulin (IVIg) therapy. / Nakano, Yumiko; Hayashi, Takeshi; Deguchi, Kentaro; Sato, Kota; Hishikawa, Nozomi; Yamashita, Toru; Ohta, Yasuyuki; Takao, Yoshiki; Morio, Tomohiro; Abe, Koji.

In: Journal of the Neurological Sciences, Vol. 361, 15.02.2016, p. 9-12.

Research output: Contribution to journalArticle

Nakano, Yumiko ; Hayashi, Takeshi ; Deguchi, Kentaro ; Sato, Kota ; Hishikawa, Nozomi ; Yamashita, Toru ; Ohta, Yasuyuki ; Takao, Yoshiki ; Morio, Tomohiro ; Abe, Koji. / Two young stroke patients associated with regular intravenous immunoglobulin (IVIg) therapy. In: Journal of the Neurological Sciences. 2016 ; Vol. 361. pp. 9-12.
@article{caaa935beadb4e5a821523fa9c9d165f,
title = "Two young stroke patients associated with regular intravenous immunoglobulin (IVIg) therapy",
abstract = "We recently experienced 2 young adult patients who developed ischemic stroke after regular intravenous immunoglobulin (IVIg) therapy for agammaglobulinemia with diagnosis of common variable immunodeficiency (CVID) in their childhood. Patient 1 was 26-year-old woman, who developed Wallenberg's syndrome 6 days after the last IVIg therapy, but had no further stroke recurrence with cilostazol later. Patient 2 was 37-year-old man, who developed recurrent cerebral infarction in the territory of bilateral lenticulostriate branches like branch atheromatous disease (BAD) several days after the IVIg therapy. However, he had no further stroke recurrence after bone marrow transplantation (BMT) therapy for his lymphoproliferative disorder. It was suggested that IVIg therapy was associated to these different types of ischemic stroke in our 2 young adult patients with minimal vascular risk factors. Although IVIg therapy is widely used as a relatively safe medication for immunodeficiency disorders or autoimmune diseases, we need to pay more attention to stroke occurrence with regular IVIg therapy.",
keywords = "Agammaglobulinemia, Intravenous immunoglobulin, Stroke, Thrombotic complication",
author = "Yumiko Nakano and Takeshi Hayashi and Kentaro Deguchi and Kota Sato and Nozomi Hishikawa and Toru Yamashita and Yasuyuki Ohta and Yoshiki Takao and Tomohiro Morio and Koji Abe",
year = "2016",
month = "2",
day = "15",
doi = "10.1016/j.jns.2015.12.001",
language = "English",
volume = "361",
pages = "9--12",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",

}

TY - JOUR

T1 - Two young stroke patients associated with regular intravenous immunoglobulin (IVIg) therapy

AU - Nakano, Yumiko

AU - Hayashi, Takeshi

AU - Deguchi, Kentaro

AU - Sato, Kota

AU - Hishikawa, Nozomi

AU - Yamashita, Toru

AU - Ohta, Yasuyuki

AU - Takao, Yoshiki

AU - Morio, Tomohiro

AU - Abe, Koji

PY - 2016/2/15

Y1 - 2016/2/15

N2 - We recently experienced 2 young adult patients who developed ischemic stroke after regular intravenous immunoglobulin (IVIg) therapy for agammaglobulinemia with diagnosis of common variable immunodeficiency (CVID) in their childhood. Patient 1 was 26-year-old woman, who developed Wallenberg's syndrome 6 days after the last IVIg therapy, but had no further stroke recurrence with cilostazol later. Patient 2 was 37-year-old man, who developed recurrent cerebral infarction in the territory of bilateral lenticulostriate branches like branch atheromatous disease (BAD) several days after the IVIg therapy. However, he had no further stroke recurrence after bone marrow transplantation (BMT) therapy for his lymphoproliferative disorder. It was suggested that IVIg therapy was associated to these different types of ischemic stroke in our 2 young adult patients with minimal vascular risk factors. Although IVIg therapy is widely used as a relatively safe medication for immunodeficiency disorders or autoimmune diseases, we need to pay more attention to stroke occurrence with regular IVIg therapy.

AB - We recently experienced 2 young adult patients who developed ischemic stroke after regular intravenous immunoglobulin (IVIg) therapy for agammaglobulinemia with diagnosis of common variable immunodeficiency (CVID) in their childhood. Patient 1 was 26-year-old woman, who developed Wallenberg's syndrome 6 days after the last IVIg therapy, but had no further stroke recurrence with cilostazol later. Patient 2 was 37-year-old man, who developed recurrent cerebral infarction in the territory of bilateral lenticulostriate branches like branch atheromatous disease (BAD) several days after the IVIg therapy. However, he had no further stroke recurrence after bone marrow transplantation (BMT) therapy for his lymphoproliferative disorder. It was suggested that IVIg therapy was associated to these different types of ischemic stroke in our 2 young adult patients with minimal vascular risk factors. Although IVIg therapy is widely used as a relatively safe medication for immunodeficiency disorders or autoimmune diseases, we need to pay more attention to stroke occurrence with regular IVIg therapy.

KW - Agammaglobulinemia

KW - Intravenous immunoglobulin

KW - Stroke

KW - Thrombotic complication

UR - http://www.scopus.com/inward/record.url?scp=84958986553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958986553&partnerID=8YFLogxK

U2 - 10.1016/j.jns.2015.12.001

DO - 10.1016/j.jns.2015.12.001

M3 - Article

C2 - 26810508

AN - SCOPUS:84958986553

VL - 361

SP - 9

EP - 12

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

ER -